Illumina, Inc. $ILMN Shares Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund reduced its holdings in Illumina, Inc. (NASDAQ:ILMN) by 5.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 97,471 shares of the life sciences company’s stock after selling 5,148 shares during the period. Illinois Municipal Retirement Fund owned about 0.06% of Illumina worth $12,014,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Illumina by 7.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after buying an additional 79 shares during the last quarter. HighPoint Advisor Group LLC raised its position in Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after acquiring an additional 80 shares in the last quarter. Toronto Dominion Bank lifted its holdings in Illumina by 0.3% in the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after acquiring an additional 92 shares during the period. Panagora Asset Management Inc. lifted its holdings in Illumina by 3.9% in the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after acquiring an additional 96 shares during the period. Finally, Venturi Wealth Management LLC boosted its position in Illumina by 4.2% in the 4th quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock worth $323,000 after purchasing an additional 99 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on ILMN shares. Barclays raised their price objective on shares of Illumina from $122.00 to $145.00 and gave the stock an “underweight” rating in a research note on Wednesday, June 24th. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Thursday, May 14th. Sanford C. Bernstein began coverage on shares of Illumina in a research report on Friday, June 26th. They set a “market perform” rating and a $185.00 price target on the stock. Finally, Guggenheim lifted their price objective on shares of Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a report on Monday, June 29th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $153.56.

Insider Activity at Illumina

In other news, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the sale, the director directly owned 2,830,452 shares of the company’s stock, valued at $463,146,860.76. This represents a 7.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,003,769 shares of company stock worth $155,710,908 in the last quarter. 2.90% of the stock is owned by insiders.

Illumina Stock Up 1.7%

Shares of ILMN opened at $190.25 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $196.66. The stock’s 50 day moving average is $165.54 and its two-hundred day moving average is $143.04. The firm has a market cap of $28.78 billion, a P/E ratio of 34.59, a PEG ratio of 3.50 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the company posted $0.97 EPS. The business’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts predict that Illumina, Inc. will post 5.21 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.